253 related articles for article (PubMed ID: 7804724)
21. Cellular therapy: scientific rationale and clinical results in the treatment of metastatic renal-cell carcinoma.
Pierce WC; Belldegrun A; Figlin RA
Semin Oncol; 1995 Feb; 22(1):74-80. PubMed ID: 7855622
[No Abstract] [Full Text] [Related]
22. Superior antitumor in vitro responses of allogeneic matched sibling compared with autologous patient CD8+ T cells.
Kausche S; Wehler T; Schnürer E; Lennerz V; Brenner W; Melchior S; Gröne M; Nonn M; Strand S; Meyer R; Ranieri E; Huber C; Falk CS; Herr W
Cancer Res; 2006 Dec; 66(23):11447-54. PubMed ID: 17145892
[TBL] [Abstract][Full Text] [Related]
23. Evidence for oligoclonal T-cell response in a metastasis of renal cell carcinoma responding to vaccination with autologous tumor cells and transfer of in vitro-sensitized vaccine-draining lymph node lymphocytes.
Weidmann E; Logan TF; Yasumura S; Kirkwood JM; Trucco M; Whiteside TL
Cancer Res; 1993 Oct; 53(20):4745-9. PubMed ID: 8402652
[TBL] [Abstract][Full Text] [Related]
24. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2.
Chang AE; Aruga A; Cameron MJ; Sondak VK; Normolle DP; Fox BA; Shu S
J Clin Oncol; 1997 Feb; 15(2):796-807. PubMed ID: 9053507
[TBL] [Abstract][Full Text] [Related]
25. [Adoptive immunotherapy and metastasized cancer of the kidney. Regulator effects of interleukin-4 on tumor infiltrating lymphocytes (TIL)].
Peyret C; Bochner B; Lee TY; Tso CL; Dekernion JB; Belldegrun A
Chirurgie; 1991; 117(9):700-9. PubMed ID: 1843670
[TBL] [Abstract][Full Text] [Related]
26. Cell therapy: achievements and perspectives.
Bordignon C; Carlo-Stella C; Colombo MP; De Vincentiis A; Lanata L; Lemoli RM; Locatelli F; Olivieri A; Rondelli D; Zanon P; Tura S
Haematologica; 1999 Dec; 84(12):1110-49. PubMed ID: 10586214
[TBL] [Abstract][Full Text] [Related]
27. Studies of the immunological effects of interleukin-2 in patients with bladder cancer and renal cell carcinoma.
Hermann GG
APMIS Suppl; 1993; 35():1-26. PubMed ID: 8251200
[No Abstract] [Full Text] [Related]
28. Adoptive immunotherapy of advanced solid tumors: an eight year clinical experience.
Semino C; Martini L; Queirolo P; Cangemi G; Costa R; Alloisio A; Ferlazzo G; Sertoli MR; Reali UM; Ratto GB; Melioli G
Anticancer Res; 1999; 19(6C):5645-9. PubMed ID: 10697634
[TBL] [Abstract][Full Text] [Related]
29. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
[TBL] [Abstract][Full Text] [Related]
30. Large scale expansion of human tumor infiltrating lymphocytes with surface-modified stimulator cells for adoptive immunotherapy.
Chin Y; Janssens J; Smeyers E; Bleus J; Zhang J; Raus J
Anticancer Res; 1992; 12(3):733-6. PubMed ID: 1622131
[TBL] [Abstract][Full Text] [Related]
31. Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck.
Whiteside TL; Letessier E; Hirabayashi H; Vitolo D; Bryant J; Barnes L; Snyderman C; Johnson JT; Myers E; Herberman RB
Cancer Res; 1993 Dec; 53(23):5654-62. PubMed ID: 8242620
[TBL] [Abstract][Full Text] [Related]
32. Mechanisms of adoptive immunotherapy: improved methods for in vivo tracking of tumor-infiltrating lymphocytes and lymphokine-activated killer cells.
Wallace PK; Palmer LD; Perry-Lalley D; Bolton ES; Alexander RB; Horan PK; Yang JC; Muirhead KA
Cancer Res; 1993 May; 53(10 Suppl):2358-67. PubMed ID: 8485722
[TBL] [Abstract][Full Text] [Related]
33. A parathyroid-hormone-related-protein (PTH-rP)-specific cytotoxic T cell response induced by in vitro stimulation of tumour-infiltrating lymphocytes derived from prostate cancer metastases, with epitope peptide-loaded autologous dendritic cells and low-dose IL-2.
Correale P; Micheli L; Vecchio MT; Sabatino M; Petrioli R; Pozzessere D; Marsili S; Giorgi G; Lozzi L; Neri P; Francini G
Br J Cancer; 2001 Nov; 85(11):1722-30. PubMed ID: 11742494
[TBL] [Abstract][Full Text] [Related]
34. [Adoptive immunotherapy by intra-arterial infusion of ATLAK or Allo-TLAK cells in patients with head and neck cancer].
Ikawa T; Eura M; Fukiage T; Murakami H; Yamasaki S; Fukuda K; Fukushima M; Arishima S; Maehara T; Ishikawa T
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1438-47. PubMed ID: 2786378
[TBL] [Abstract][Full Text] [Related]
35. [An experimental study of the antitumor activity of tumor-infiltrating lymphocytes (TIL) in human tongue carcinoma in vitro].
Guo W
Zhonghua Kou Qiang Yi Xue Za Zhi; 1992 Sep; 27(5):259-61, 318. PubMed ID: 1306434
[TBL] [Abstract][Full Text] [Related]
36. Adoptive cellular therapy.
Hoffman DM; Gitlitz BJ; Belldegrun A; Figlin RA
Semin Oncol; 2000 Apr; 27(2):221-33. PubMed ID: 10768601
[TBL] [Abstract][Full Text] [Related]
37. Postoperative immunotherapy for patients with hepatocarcinoma using tumor-infiltrating lymphocytes.
Wang Y; Chen H; Wu M; Bao J; Cong W; Wang H
Chin Med J (Engl); 1997 Feb; 110(2):114-7. PubMed ID: 9594281
[TBL] [Abstract][Full Text] [Related]
38. Human tumor infiltrating lymphocytes. Analysis of lymphokine mRNA expression and relevance to cancer immunotherapy.
Belldegrun A; Kasid A; Uppenkamp M; Topalian SL; Rosenberg SA
J Immunol; 1989 Jun; 142(12):4520-6. PubMed ID: 2723437
[TBL] [Abstract][Full Text] [Related]
39. [Adoptive immunotherapy in patients with multiple hepatic cancers using lymphokine activated killer cells (LAK) and interleukin-2].
Kanai T; Monden M; Takeda T; Gotoh M; Sakon M; Umeshita K; Hasuike Y; Sakita I; Nakano H; Yoshida T
Gan To Kagaku Ryoho; 1993 Aug; 20(11):1457-60. PubMed ID: 8396896
[TBL] [Abstract][Full Text] [Related]
40. [A new therapeutic concept in the treatment of metastatic cancers of the kidney: the TIL (tumor infiltrating lymphocytes)].
Peyret C
J Urol (Paris); 1991; 97(2):63-71. PubMed ID: 2071925
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
